Skip to main content
Download PDF
  • Research article
  • Open access
  • Published:

Substantial health and economic burden of COVID-19 during the year after acute illness among US adults not at high risk of severe COVID-19

BMC Medicine volume 22, Article number: 47 (2024) Cite this article

Abstract

Background

Patients recovering from SARS-CoV-2 infection and acute COVID-19 illness can experience a range of long-term post-acute effects. The potential clinical and economic burden of these outcomes in the USA is unclear. We evaluated diagnoses, medications, healthcare utilization, and medical costs before and after acute COVID-19 illness in US patients who were not at high risk of severe COVID-19.

Methods

This study included eligible adults who were diagnosed with COVID-19 from April 1 to May 31, 2020, who were 18 − 64 years of age, and enrolled within Optum’s de-identified Clinformatics® Data Mart Database for 12 months before and 13 months after COVID-19 diagnosis. Patients with any condition or risk factor placing them at high risk of progression to severe COVID-19 were excluded. Percentages of diagnoses, medications, healthcare utilization, and costs were calculated during baseline (12 months preceding diagnosis) and the post-acute phase (12 months after the 30-day acute phase of COVID-19). Data were stratified into 3 cohorts according to disposition during acute COVID-19 illness (i.e., not hospitalized, hospitalized without intensive care unit [ICU] admission, or admitted to the ICU).

Results

The study included 3792 patients; 56.5% of patients were men, 44% were White, and 94% did not require hospitalization. Compared with baseline, patients during the post-acute phase had percentage increases in the diagnosis of the following disorders: blood (166%), endocrine and metabolic (123%), nervous system (115%), digestive system (76%), and mental and behavioral (75%), along with increases in related prescriptions. Substantial increases in all measures of healthcare utilization were observed among all 3 cohorts. Total medical costs increased by 178% during the post-acute phase. Those who were hospitalized with or without ICU admission during the acute phase had the greatest increases in comorbidities and healthcare resource utilization. However, the burden was apparent across all cohorts.

Conclusions

As evidenced by resource use in the post-acute phase, COVID-19 places a significant long-term clinical and economic burden among US individuals, even among patients whose acute infection did not merit hospitalization.

Peer Review reports

Background

Nearly 20% of adults diagnosed with COVID-19 experience symptoms for ≥ 3 months after first contracting the virus [1, 2]. These highly variable signs and symptoms, often termed post-COVID conditions, can either begin at the time of initial infection and persist for several months or may be new symptoms or syndromes that develop only after the acute phase of COVID-19 [3,4,5]. For many individuals, post-COVID conditions involve multiple organ systems and significantly impair daily functioning and productivity [6]. Although a universally accepted definition and timeframe of the condition has not yet been developed, a clinical diagnosis of post-acute sequelae of COVID-19 (PASC) was assigned an International Classification of Diseases 10 (ICD-10) code (U09.9) in October of 2021 [7, 8].

Although it is widely accepted that older age, belonging to racial and ethnic minority groups, and certain underlying medical conditions are associated with an increased risk of progression to severe COVID-19 upon initial infection [9], the characteristics associated with risk of developing post-COVID conditions are largely unknown. Some overlapping but distinct risk factors, such as female sex and older age, have been identified, as well as an association between acute COVID-19 severity and duration of symptoms [10,11,12]. However, numerous reports from several countries have identified high rates of post-COVID conditions, even among patient cohorts with mixed disease severity or mild cases of COVID-19 [4, 13,14,15]. In the current landscape where mild COVID-19 illness is becoming more common, owing both to vaccination [16] and the highly transmissible but potentially less virulent Omicron strain [16,17,18,19], it is necessary to understand the burden on health and healthcare systems after an acute COVID-19 infection among patients who do not have underlying comorbidities and who did not require hospitalization for acute COVID-19. An understanding of long-term health effects after acute COVID-19 infection, the populations at risk, and the associated strain on healthcare systems is imperative to inform accurate estimations of the evolving clinical and economic burden of COVID-19.

We conducted a descriptive, retrospective analysis of morbidity, healthcare resource utilization, and costs associated with the post-acute phase of COVID-19 among adult patients aged < 65 years and without any underlying conditions placing them at high risk of progression to severe disease. In a companion report [20], we describe an identical analysis conducted among patients with ≥ 1 underlying condition or who were aged ≥ 65 years. The companion report and the current report were both purely descriptive with no formal statistical comparisons, with the goal to present a broad and unbiased dataset that can inform future hypothesis generation.

Methods

This descriptive, retrospective cohort study compared baseline healthcare utilization data from patients during the year before contracting COVID-19 with their healthcare utilization data during the year after recovery from the 30-day acute phase (from day 31 through day 390 after diagnosis). All patients served as their own control for evaluation of diagnoses, medications, healthcare utilization, and costs before compared with after acute COVID-19. Details regarding the study design, data source, and inclusion and exclusion criteria have been included in the companion manuscript regarding individuals at high risk of progression to severe COVID-19 [20].

Briefly, enrolled patients were diagnosed with COVID-19 (ICD-10 diagnosis code of U07.1) between April 1 and May 31, 2020 (the index period). Information regarding diagnoses, medications, healthcare utilization, and costs were collected from Optum’s de-identified Clinformatics® Data Mart Database (CDM), which contains patient-level information derived from administrative health claims of commercial and Medicare Advantage plan members. Data extracted from CDM were not sufficient to determine whether any post-COVID-19 diagnosis, medication prescription, or healthcare utilization was specifically caused by COVID-19; therefore, it was unknown whether any individual diagnosis or adverse health outcome was truly a “post-COVID condition” or was caused by unrelated factors [5]. Eligible patients were continuously enrolled in CDM (with gaps of ≤ 45 days permitted) over the 12 months before and 13 months after COVID-19 diagnosis and were aged 18 to 64 years on the index date. Patients were excluded if they had a diagnosis code (ICD-10-Clinical Modification [ICD-10-CM]), procedure code (ICD-10-Procedure Coding System [ICD-10-PCS], Current Procedural Terminology [CPT®], Healthcare Common Procedures Coding System [HCPCS]), or National Drug Code (NDC) for any condition placing them at high risk of progression to severe COVID-19, per CDC definitions as of October 14, 2021 [9], within the 12 months before the index date. Additional exclusion criteria were hospitalizations for ≥ 5 consecutive days during the baseline phase; any time spent at a long-term care facility, skilled nursing facility, inpatient rehabilitation, or hospice during baseline or at index date; an ICD-10 code for confirmed COVID-19 before the index period; or death during the acute phase of COVID-19.

The top 500 ICD-10 diagnosis codes were analyzed by ICD-10 code chapter (a system of organization based on the most affected organ systems or types of injury/disease), and medications were categorized according to Uniform System of Classification class. All diagnosis and medication categories applicable to < 2% of the overall population during the baseline phase were excluded from analysis. The “biologics” category was also excluded based on incomplete data capture. Standard medical cost means, standard deviations, medians, and quartiles were calculated using the number of patients with a related visit or service, and nonzero costs were calculated using the number of patients with a cost > 0 associated with that visit or service. No adjustments were made for patients who died during the 12-month post-acute phase; all deaths that occurred during the post-acute phase were accounted for and reported. Absolute and relative change from baseline to the post-acute phase were calculated for each outcome where possible using frequency counts. To better understand the relationship between post-acute outcomes and initial infection severity, all data were presented for the overall population and stratified by patient disposition during the acute phase of COVID-19 (within 30 days after diagnosis): not hospitalized, hospitalized without intensive care unit (ICU) admission, or admitted to the ICU. Analyses were performed using SAS version 9.4 (SAS, Cary, NC), and no statistical inference tests were conducted.

Results

Patient population

Overall, the cohort included 3792 patients with a median (quartile 1; quartile 3) age of 40 (31; 50) years (Table 1). A slight majority of patients were male (56.5%), and 44.0% of patients were White. When categorized by disposition during the acute phase of COVID-19, 3546 patients (93.5%) did not require hospitalization, 164 (4.3%) were hospitalized without ICU admission, and 82 (2.2%) were admitted to the ICU. Patients who were male, Black, or aged 50 to 64 years were more highly represented within the cohort with ICU admission than within the overall population.

Table 1 Baseline demographic and clinical characteristics
Full size table

Most patients (95.2%) were diagnosed with COVID-19 in the outpatient setting (Table 1). Very few patients (0.2% of those hospitalized at any time during the acute phase) had hospital stays that lasted > 30 days, overlapping the acute and post-acute phases of the study. None of the patients died during the post-acute phase. A full list of reasons for exclusion from the analysis is shown in Table S1.

Diagnoses

In the overall population, the frequency of ICD-10 diagnosis codes increased within several chapters (diagnosis categories) between the baseline and post-acute phases (Fig. 1). The number of patients with “diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism” increased by 166.0% from baseline, as well as a 123.2% increase in “endocrine, nutritional, and metabolic diseases,” a 115.2% increase in “diseases of the nervous system,” a 76.3% increase in “diseases of the digestive system,” and a 74.6% increase in “mental and behavioral disorders” (Fig. 1). Frequencies of diagnoses within these chapters increased within all 3 cohorts (Table 2), with the smallest percentage increases observed among patients who were not hospitalized for acute COVID-19 and the largest percentage increases observed among patients who were admitted to the ICU.

Fig. 1
figure 1

Percentage change from baseline to post-acute phase in ICD-10 diagnoses in the overall population (N = 3792). Chapters include those with a prevalence of ≥ 2% in the baseline population

ICD-10 International Classification of Diseases 10th Revision

Full size image
Table 2 Diagnoses during the baseline and post-acute phasesa stratified by disposition during acute COVID-19
Full size table

The greatest decrease observed within the overall cohort was a − 26.5% change from baseline in the frequency of “diseases of the respiratory system” (Fig. 1). This value reflected a combination of decreased acute diagnoses, as well as a 73.0% increase in the frequency of “chronic lower respiratory diseases” (Fig. 2).

Fig. 2
figure 2

Diagnoses of the respiratory system during baseline and post-acute phases in the overall population (N = 3792). Diagnoses include those with a prevalence of ≥ 2% in the baseline population and are categorized according to whether they are chronic, acute, or other/both

ICD-10 International Classification of Diseases 10th Revision

Full size image

Medication use

In the overall population, medications from several different classes were prescribed in greater numbers during the post-acute phase compared with baseline (Table 3). The greatest observed changes were a 188.6% increase in hormones (primarily corticoids and glucocorticoids; Table S2), a 113.1% increase in vascular agents, a 62.7% increase in musculoskeletal agents, a 61.5% increase in antihyperlipidemic agents, and a 61.0% increase in neurological/neuromuscular agents. In contrast, there was also a 73.5% decrease in prescriptions of cough/cold/flu preparations and a 48.8% decrease in antivirals.

Table 3 New medication prescriptions during baseline and post-acute phasesa in the overall population (N = 3792)
Full size table

For most medication classes, increases in prescriptions from the baseline to the post-acute phase were observed across all 3 cohorts but were generally greatest among those who were admitted to the ICU for acute COVID-19 (Table 4). As an exception, the magnitude of the percentage increases in hormone prescriptions was relatively consistent across cohorts.

Table 4 New medication prescriptions during the baseline and post-acute phasesa stratified by disposition during acute COVID-19
Full size table

Prescription increases were also observed within several medication classes that were not included in the main analysis because they were prescribed to < 2% of the overall cohort during the baseline phase (Table S3). These included increases of > 100% within the classes of hemostatic modifiers, diabetes therapy, cardiac agents, and blood factors.

Medical care and hospitalizations

Between the baseline and post-acute phases, increases were observed across all measures of healthcare utilization in the overall population and among all 3 cohorts (Tables 5 and 6). The greatest changes were related to inpatient resources: a 3100% increase in inpatient lab tests, a 3000% increase in total days spent in the ICU, a 1269% increase in length of stay (LOS), and a 527% increase in number of hospitalizations (Table 5). With the exception of emergency department (ED) visits, increases in all measures of healthcare utilization were greatest among those who were admitted to the ICU for acute COVID-19 (Table 6).

Table 5 Healthcare resource utilization during the baseline and post-acute phasesa in the overall population (N = 3792)
Full size table
Table 6 Healthcare resource utilization during the baseline and post-acute phasesa stratified by disposition during acute COVID-19
Full size table

Increases in healthcare utilization were also represented by a shift in patterns of discharge status (Table 7). The percentages of hospitalized patients who were discharged to home or self-care were 95.5% during the baseline phase and 65.2% during the post-acute phase. During the post-acute phase, larger percentages of patients were discharged to either a home care service or other facility (such as a hospice or skilled nursing facility), were transferred within the institution, or had an unknown discharge status.

Table 7 Hospital discharge status during the baseline and post-acute phasesa in the overall population (N = 3792)
Full size table

Healthcare costs

During the post-acute phase, total medical costs (including prescription, inpatient, and outpatient costs) increased from baseline by 177.9% in the overall population (Table 8). When stratified by disposition during acute COVID-19 illness, cost increases were highest among those admitted to the ICU during acute COVID-19 (+ 1694.6%) but were also apparent among those who were not hospitalized (+ 138.4%) (Table 9). Increases of varying magnitudes were observed across all measures of healthcare costs and across all cohorts.

Table 8 Medical costs during the baseline and post-acute phasesa in the overall population (N = 3792)
Full size table
Table 9 Medical costs during the baseline and post-acute phasesa stratified by disposition during acute COVID-19
Full size table

Matching the trends in healthcare utilization (Table 5), the greatest cost increases were associated with inpatient hospitalizations, including readmissions within 30 days of hospital discharge (Table 8). Smaller but substantial increases were associated with outpatient visits, including ED visits, and prescription claims. With the exception of ED visit costs, all cost increases were greatest among those admitted to the ICU during acute COVID-19 (Table 9).

Discussion

This retrospective analysis of adults aged < 65 years without any underlying high-risk conditions identified increases in diagnoses, medical prescriptions, healthcare utilization events, and associated costs during the year after the acute phase of COVID-19. As observed previously [10] and in our companion manuscript regarding high-risk patients [20], those who were hospitalized with or without ICU admission during the acute phase had the greatest increase in comorbidities and healthcare resource utilization burden. However, the burden was apparent across all 3 cohorts, including those who were not hospitalized for COVID-19.

Many of the changes observed in this cohort were similar to observations among high-risk patients [20]. Most notably, the greatest increase in both studies was in the percentages of patients with blood-related diseases, which has been identified previously as a feature of post-COVID conditions [21]. In the present study, new diagnoses of blood disorders increased by > 150% during the post-acute phase compared with baseline, even among the cohort of patients who were not hospitalized during the acute phase of illness. New diagnoses of neurological and psychiatric diseases also increased in the year following acute COVID-19 in both patients with and without any risk factors for severe COVID-19, regardless of the level of care setting during the acute phase of illness, which is consistent with previous reports of long-term COVID-19 sequelae [22, 23]. We observed a 27% decrease in respiratory disease during the post-acute phase; similar to results from the high-risk population, this decrease reflected a large increase in chronic lower respiratory diseases that was outweighed by a combination of smaller decreases in acute upper and lower respiratory infections, influenza, and pneumonia. Distinct from observations in high-risk patients, analysis of the cohort described here also revealed a 123% increase in endocrine, nutritional, and metabolic diseases and a 76% increase in diseases of the digestive system.

The analysis of medication use demonstrated the greatest increase in hormone prescriptions, including primarily injectable, oral, and topical glucocorticoids and corticoids (e.g., prednisone, methylprednisolone, and dexamethasone). These medications were typically not prescribed during the baseline phase and were likely being used for the treatment of persistent COVID-19 symptoms, such as joint stiffness and muscle pain [24]. Increases in hormone use were followed by vascular and musculoskeletal agents, and increases across the 3 classes of medications were observed across all levels of care during acute COVID-19. Those results were unique to this population and not observed among high-risk patients [20]. However, when the analysis was conducted including medication classes prescribed to < 2% of the baseline population, a 277% increase in hemostatic modifier prescriptions and a 106% increase in blood factor prescriptions were identified, consistent with results of the same analysis among high-risk patients. It is logical that several of the medication classes prescribed to ≥ 2% of the baseline population in the high-risk patient cohort were prescribed to < 2% of the baseline population in the cohort evaluated here because these patients were overall younger and healthier at baseline.

Healthcare resource utilization and costs were higher during the post-acute phase compared with the baseline phase for all evaluated measures, including outpatient visits, ED visits, inpatient visits and LOS, ICU admission and LOS, 30-day readmissions, and prescriptions. The likelihood of patients being discharged to another hospital department or long-term care facility also increased. The most striking cost changes were observed across measures related to inpatient resources, including an overall increase in inpatient visit costs of nearly 950% in the post-acute phase and resulting in a 178% increase in total medical costs in the overall population.

Cost increases varied in magnitude but were observed for every healthcare outcome across all categories of the acute COVID-19 level of care. Even among those who were not hospitalized during the acute phase of COVID-19, inpatient visit costs during the post-acute phase increased by 578%, outpatient visit costs increased by 139%, and total medical costs increased by 138%. This trend was similar to observations made in the cohort of high-risk patients [20] but was a more surprising result given that the patients in the cohort described here were aged < 65 years and lacked any comorbid conditions placing them at risk of severe COVID-19.

Taken together, health and healthcare resource use results suggest that the risk factors associated with developing post-COVID conditions may be distinct from the risk factors that predict severity of acute disease. Similarly to how biomarkers have been characterized to predict the course of acute COVID-19 [25], there may be a unique set of biomarkers associated with the development of long-term adverse health outcomes. One recent study identified biomarkers associated with vascular transformation among long-COVID patients [26], which is consistent with findings in our present study and companion report regarding a high prevalence of blood-related diseases in the post-acute phase. Importantly, regardless of the mechanisms involved, results indicate that the health and economic impacts of COVID-19 may extend beyond the acute phase of illness even among the wide swath of the population that is relatively young and healthy and has mild symptoms upon infection.

Although limited data are available on strategies to reduce the risk of post-COVID conditions, vaccination against COVID-19 appears to be protective. In a recent prospective study from Antonelli and colleagues [27], fully vaccinated adults with breakthrough infections were less likely than unvaccinated controls to experience symptoms of COVID-19 lasting ≥ 28 days; the effect was observed among both older adults and adults aged < 60 years. In a retrospective cohort study from Taquet and colleagues [28], vaccination among adults who contracted COVID-19 was associated with steep reductions in risk of several long-term adverse health outcomes. Although authors of the Taquet study did not find COVID-19 vaccination to be associated with reduced risk of what they termed “long COVID features” (a collection of specific abdominal, respiratory, psychiatric, and pain-related symptoms), they did identify significantly lower risk of many of the diagnoses discussed in the present report, including blood disorders, muscle disease, certain neurological conditions, and chronic respiratory conditions. Because these outcomes were measured over a 6-month period after infection, they included diagnoses during both the acute and post-acute phases. Highlighting the importance of vaccination even among those not in a high-risk group, protective effects of vaccination against many post-acute sequelae were most robust among individuals aged < 60 years.

Recently, emerging data have also suggested that antiviral treatment for COVID-19, such as nirmatrelvir/ritonavir (Paxlovid®, Pfizer Inc, New York, NY, USA), may reduce the likelihood of developing PASC. In a large study of patients from the Veterans Affairs database [29], authors found that individuals prescribed nirmatrelvir-ritonavir during the acute phase of COVID-19 had reduced risks of prespecified sequelae (including cardiovascular, hematologic, and neurologic disorders), post-acute hospitalization, and post-acute death, regardless of vaccination status. A small case series has furthermore suggested that nirmatrelvir administered during the post-acute phase may alleviate long-term symptom burden [30], although more systematic study of these effects is warranted before conclusions can be drawn.

Our study had several strengths. Primarily, having all patients serve as their own control inherently adjusted for potential confounders, such as demographics and health-seeking behavior. To our knowledge, this was also the first study that evaluated the economic impact of post-acute COVID-19 in adults who were < 65 years of age and had no underlying comorbidities placing them at risk of severe acute COVID-19. The ability to pair these broad, descriptive data with the identical analysis in a cohort of adults with high-risk conditions [20] is of significant value in understanding differences between characteristics that predict acute versus post-acute COVID-19 outcomes. A limitation of our study was that the cohort was confined to individuals with commercial insurance; all enrolled participants were also diagnosed early in the pandemic and survived the acute phase of COVID-19. Additionally, there was no method of confirming that any adverse health outcomes reported here were related to COVID-19. There was also a possibility for incomplete data capture owing to nonbillable diagnoses, and our results may have been influenced by surveillance bias, whereby contracting COVID-19 led to higher medical scrutiny following diagnosis. Finally, the study was conducted in a period before vaccination and previous SARS-CoV-2 infection and before the emergence of SARs-CoV-2 variants of concern. Such factors could limit the generalizability of the findings to the present. Baseline assessments were also performed in the prepandemic period; whereas post-acute COVID-19 assessments were performed during a public health emergency in which healthcare practices could have changed. Thus, clinical burden and health costs during the post-acute COVID-19 period may have been impacted by altered heathcare practices.

Conclusion

Our data suggest that the health and economic burden of COVID-19 stretches well beyond the acute phase of illness, even among younger individuals without preexisting conditions whose acute infection did not merit hospitalization. Understanding the nature and extent of post-COVID conditions, as well as the unique populations at risk, is critical to evaluating the true societal cost–benefit of interventions such as COVID-19 vaccination and treatment.

Availability of data and materials

Upon request, and subject to review, Pfizer will provide the data that support the findings of this study. Subject to certain criteria, conditions, and exceptions, Pfizer may also provide access to the related individual de-identified participant data. See https://www.pfizer.com/science/clinical-trials/trial-data-and-results for more information.

Abbreviations

ACTH:

Adrenocorticotropic hormone

CDC:

US Centers for Disease Control and Prevention

CDM:

Optum’s de-identified Clinformatics® Data Mart Database

CPT:

Current Procedural Terminology

ED:

Emergency department

HCPCS:

Healthcare Common Procedure Coding System

ICD-10:

International Classification of Diseases, 10th Revision

ICD-10-CM:

International Classification of Diseases, 10th Revision, Clinical Modification

ICD-10-PCS:

International Classification of Diseases, 10th Revision, Procedure Coding System

ICU:

Intensive care unit

LOS:

Length of stay

LTCF:

Long-term care facility

NC:

Not calculable

NDC:

National Drug Code

PASC:

Post-acute sequelae of COVID-19

Q1:

Quartile 1

Q3:

Quartile 3

SAS:

Statistical analysis software

SNF:

Skilled nursing facility

USC:

Uniform System of Classification

USD:

United States dollars

References

  1. Bull-Otterson L, Baca S, Saydah S, Boehmer TK, Adjei S, Gray S, et al. Post-COVID conditions among adult COVID-19 survivors aged 18–64 and ≥65 years — United States, March 2020–November 2021. MMWR Morb Mortal Wkly Rep. 2022;71(21):713–7.

    Article  CAS  PubMed Central  Google Scholar 

  2. Centers for Disease Control and Prevention. Nearly One in Five American Adults Who Have Had COVID-19 Still Have "Long COVID". Available at: https://www.cdc.gov/nchs/pressroom/nchs_press_releases/2022/20220622.htm. Accessed 6 Sept 2022.

  3. World Health Organization. A Clinical Case Definition of Post COVID-19 Condition by a Delphi Consensus. World Health Organization. Available at: https://www.who.int/publications/i/item/WHO-2019-nCoV-Post_COVID-19_condition-Clinical_case_definition-2021.1. Accessed 8 Jun 2022.

  4. Amenta EM, Spallone A, Rodriguez-Barradas MC, El Sahly HM, Atmar RL, Kulkarni PA. Postacute COVID-19: an overview and approach to classification. Open Forum Infect Dis. 2020;7(12):ofaa509.

    Article  PubMed  PubMed Central  Google Scholar 

  5. Centers for Disease Control and Prevention. Post-COVID Conditions: Information for Healthcare Providers. Available at: https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-care/post-covid-conditions.html. Accessed 23 Jun 2022.

  6. Davis HE, Assaf GS, McCorkell L, Wei H, Low RJ, Re’em Y, et al. Characterizing long COVID in an international cohort: 7 months of symptoms and their impact. EClinicalMedicine. 2021;38:101019.

    Article  PubMed  PubMed Central  Google Scholar 

  7. Centers for Disease Control and Prevention. New ICD-10-CM Code for Post-COVID Conditions, Following the 2019 Novel Coronavirus (COVID-19). Centers for Disease Control and Prevention. Available at: https://www.cdc.gov/nchs/data/icd/Announcement-New-ICD-code-for-Post-COVID-Condition-April-2022-final.pdf. Accessed 8 Jun 2022.

  8. McGrath LJ, Scott AM, Surinach A, Chambers R, Benigno M, Malhotra D. Use of the post-acute sequelae of COVID-19 diagnosis code in routine clinical practice in the US. JAMA Netw Open. 2022;5(5):e2235089.

    Article  PubMed  PubMed Central  Google Scholar 

  9. Centers for Disease Control and Prevention. Underlying Medical Conditions Associated With Higher Risk for Severe COVID-19: Information for Healthcare Professionals. Available at: https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-care/underlyingconditions.html. Accessed 9 Jan 2022.

  10. Sudre CH, Murray B, Varsavsky T, Graham MS, Penfold RS, Bowyer RC, et al. Attributes and predictors of long COVID. Nat Med. 2021;27(4):626–31.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Bai F, Tomasoni D, Falcinella C, Barbanotti D, Castoldi R, Mule G, et al. Female gender is associated with long COVID syndrome: a prospective cohort study. Clin Microbiol Infect. 2022;28(4):611.e619–611.e616.

    Article  Google Scholar 

  12. Yoo SM, Liu TC, Motwani Y, Sim MS, Viswanathan N, Samras N, et al. Factors associated with post-acute sequelae of SARS-CoV-2 (PASC) after diagnosis of symptomatic COVID-19 in the inpatient and outpatient setting in a diverse cohort. J Gen Intern Med. 2022;37(8):1988–95.

    Article  PubMed  PubMed Central  Google Scholar 

  13. Groff D, Sun A, Ssentongo AE, Ba DM, Parsons N, Poudel GR, et al. Short-term and long-term rates of postacute sequelae of SARS-CoV-2 infection: a systematic review. JAMA Netw Open. 2021;4(10):e2128568.

    Article  PubMed  PubMed Central  Google Scholar 

  14. Petersen MS, Kristiansen MF, Hanusson KD, Danielsen ME, B AS, Gaini S, et al. Long COVID in the Faroe Islands: a longitudinal study among nonhospitalized patients. Clin Infect Dis. 2021;73(11):e4058–63.

    Article  CAS  PubMed  Google Scholar 

  15. Augustin M, Schommers P, Stecher M, Dewald F, Gieselmann L, Gruell H, et al. Post-COVID syndrome in non-hospitalised patients with COVID-19: a longitudinal prospective cohort study. Lancet Reg Health Eur. 2021;6:100122.

    Article  PubMed  PubMed Central  Google Scholar 

  16. Chenchula S, Karunakaran P, Sharma S, Chavan M. Current evidence on efficacy of COVID-19 booster dose vaccination against the Omicron variant: a systematic review. J Med Virol. 2022;94(7):2969–76.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Zhao H, Lu L, Peng Z, Chen LL, Meng X, Zhang C, et al. SARS-CoV-2 Omicron variant shows less efficient replication and fusion activity when compared with Delta variant in TMPRSS2-expressed cells. Emerg Microbes Infect. 2022;11(1):277–83.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Abdullah F, Myers J, Basu D, Tintinger G, Ueckermann V, Mathebula M, et al. Decreased severity of disease during the first global Omicron variant COVID-19 outbreak in a large hospital in Tshwane. South Africa Int J Infect Dis. 2022;116:38–42.

    Article  CAS  PubMed  Google Scholar 

  19. Meo SA, Meo AS, Al-Jassir FF, Klonoff DC. Omicron SARS-CoV-2 new variant: global prevalence and biological and clinical characteristics. Eur Rev Med Pharmacol Sci. 2021;25(24):8012–8.

    CAS  PubMed  Google Scholar 

  20. Scott A, Ansari W, Khan F, Chambers R, Benigno M, Di Fusco M, et al. Substantial health and economic burden of COVID‑19 during the year after acute illness among US adults at high risk of severe COVID‑19. BMC Med. 2022. https://doi.org/10.1186/s12916-023-03234-6.

  21. Pretorius E, Vlok M, Venter C, Bezuidenhout JA, Laubscher GJ, Steenkamp J, et al. Persistent clotting protein pathology in long COVID/post-acute sequelae of COVID-19 (PASC) is accompanied by increased levels of antiplasmin. Cardiovasc Diabetol. 2021;20(1):172.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. Lamontagne SJ, Winters MF, Pizzagalli DA, Olmstead MC. Post-acute sequelae of COVID-19: evidence of mood & cognitive impairment. Brain Behav Immun Health. 2021;17:100347.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Houben-Wilke S, Goertz YM, Delbressine JM, Vaes AW, Meys R, Machado FV, et al. The impact of long COVID-19 on mental health: observational 6-month follow-up study. JMIR Ment Health. 2022;9(2):e33704.

    Article  PubMed  PubMed Central  Google Scholar 

  24. Utrero-Rico A, Ruiz-Ruigomez M, Laguna-Goya R, Arrieta-Ortubay E, Chivite-Lacaba M, Gonzalez-Cuadrado C, et al. A short corticosteroid course reduces symptoms and immunological alterations underlying long-COVID. Biomedicines. 2021;9(11):1540.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Samprathi M, Jayashree M. Biomarkers in COVID-19: an up-to-date review. Front Pediatr. 2020;8:607647.

    Article  PubMed  Google Scholar 

  26. Patel MA, Knauer MJ, Nicholson M, Daley M, Van Nynatten LR, Martin C, et al. Elevated vascular transformation blood biomarkers in long-COVID indicate angiogenesis as a key pathophysiological mechanism. Mol Med. 2022;28(1):122.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Antonelli M, Penfold RS, Merino J, Sudre CH, Molteni E, Berry S, et al. Risk factors and disease profile of post-vaccination SARS-CoV-2 infection in UK users of the COVID Symptom Study app: a prospective, community-based, nested, case-control study. Lancet Infect Dis. 2022;22(1):43–55.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. Taquet M, Dercon Q, Harrison PJ. Six-month sequelae of post-vaccination SARS-CoV-2 infection: a retrospective cohort study of 10,024 breakthrough infections. Brain Behav Immun. 2022;103:154–62.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. Xie Y, Choi T, Al-Aly Z. Nirmatrelvir and the risk of post-acute sequelae of COVID-19. medRxiv. Preprint posted online November 5, 2022. https://doi.org/10.1101/2022.11.03.22281783.

  30. Peluso MJ, Anglin K, Durstenfeld MS, Martin JN, Kelly JD, Hsue PY, et al. Effect of oral nirmatrelvir on long COVID symptoms: 4 cases and rationale for systematic studies. Pathog Immun. 2022;7(1):95–103.

    PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

The authors would like to thank Farid Khan, Manuela di Fusco, Leah McGrath, Deepa Malhotra, Jennifer Nguyen, and Jessica E. Atwell of Pfizer Inc for their support in the study design and their contributions to this paper. Programming support and expertise were provided by Klaudia Niezabitowska and Kirsten Astbury of Quanticate. Editorial/medical writing support was provided by Anna Stern, PhD, of ICON (Blue Bell, PA, USA), and was funded by Pfizer Inc.

Funding

This work was supported by Pfizer Inc.

Author information

Authors and Affiliations

  1. Global Real World Evidence, Pfizer Inc, 235 East 42nd Street, New York, NY, 10017, USA

    Amie Scott & Michael Benigno

  2. Global HEOR, Pfizer Inc, New York, NY, USA

    Wajeeha Ansari

  3. Global Product Development Statistics, Pfizer Inc, New York, NY, USA

    Richard Chambers

  4. Global Biometrics and Data Management, Pfizer Inc, Groton, CT, USA

    Maya Reimbaeva

  5. Quanticate, Warsaw, Poland

    Tomasz Mikolajczyk

  6. Medical Affairs, Pfizer Inc, New York, NY, USA

    Florin Draica

  7. Medical Affairs, Pfizer Ltd, Tadworth, Surrey, UK

    Joanna Atkinson

Authors
  1. Amie Scott
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Wajeeha Ansari
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Richard Chambers
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Maya Reimbaeva
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Tomasz Mikolajczyk
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Michael Benigno
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Florin Draica
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Joanna Atkinson
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

AS, WA, RC, MB, FD, and JA contributed to the study concept and design. MR, TM, RC, and AS analyzed the patient data. All authors interpreted the data and read and approved the final manuscript.

Corresponding author

Correspondence to Amie Scott.

Ethics declarations

Ethics approval and consent to participate

This study was considered exempt from review and the need for informed consent by Sterling institutional review board due to the use of de-identified data.

Consent for publication

Not applicable.

Competing interests

AS, WA, RC, MR, MB, FD, and JA are employees of Pfizer Inc and may hold stock or stock options. TM is an employee of Quanticate, which receives consulting fees from Pfizer Inc.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information

Additional file 1: Table S1.

Reasons for Exclusion From the Study. ICD-10 International Classification of Diseases, 10th Revision, LTCF long-term care facility, SNF skilled nursing facility. aThere is no accurate date of death available, only month and year of death, so it was approximated to the last day of the month.

Additional file 2: Table S2.

Hormone Prescriptions During the Baseline and Post-Acute Phasea in the Overall Population (N=3792)b. ACTH adrenocorticotropic hormone, NC not calculable, USC Uniform System of Classification. aThe baseline period was the 12 months before the index date, and the post-acute phase spanned from 1 to 13 months after the index date. bIncludes all prescriptions, including those prescribed to <2% of the baseline population (which were excluded from the main analysis).

Additional file 3: Table S3.

New Medication Prescriptions With a ≥100% Increase From the Baseline to the Post-Acute Phasea in the Overall Population (N=3792)b. USC Uniform System of Classification. aThe baseline period was the 12 months before the index date, and the post-acute phase spanned from 1 to 13 months after the index date. bIncludes all prescriptions, including those prescribed to <2% of the baseline population (which were excluded from the main analysis).

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Scott, A., Ansari, W., Chambers, R. et al. Substantial health and economic burden of COVID-19 during the year after acute illness among US adults not at high risk of severe COVID-19. BMC Med 22, 47 (2024). https://doi.org/10.1186/s12916-023-03235-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1186/s12916-023-03235-5

Keywords

BMC Medicine

ISSN: 1741-7015

Contact us